14Jan/14

Rexahn Pharma (RNN) Initiates Archexin Proof-of-Concept Study in RCC – StreetInsider.com (subscription)

Rexahn Pharma (RNN) Initiates Archexin Proof-of-Concept Study in RCC
StreetInsider.com (subscription)
The Phase IIa Archexin proof-of-concept clinical trial is a multi-center study designed to evaluate the efficacy of Archexin in combination with everolimus (Afinitor®) to treat metastatic RCC patients and will be conducted in two stages. Stage 1 will

and more »